MX2019010086A - Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1. - Google Patents

Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1.

Info

Publication number
MX2019010086A
MX2019010086A MX2019010086A MX2019010086A MX2019010086A MX 2019010086 A MX2019010086 A MX 2019010086A MX 2019010086 A MX2019010086 A MX 2019010086A MX 2019010086 A MX2019010086 A MX 2019010086A MX 2019010086 A MX2019010086 A MX 2019010086A
Authority
MX
Mexico
Prior art keywords
combination
ceritinib
antibody molecule
cancer
dosing schedule
Prior art date
Application number
MX2019010086A
Other languages
English (en)
Inventor
Jeffrey Scott
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2019010086A publication Critical patent/MX2019010086A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere al campo de la farmacia, particularmente al ceritinib y un inhibidor de PD-1 para uso en el tratamiento del cáncer. Específicamente, la invención se refiere a una combinación farmacéutica que comprende ceritinib, o una sal farmacéuticamente aceptable del mismo, y un inhibidor de PD-1, o una sal farmacéuticamente aceptable del mismo, para usar en el tratamiento del cáncer, a un método para el tratamiento del cáncer que implica administrar la combinación y al uso de la combinación para la fabricación de un medicamento para el tratamiento del cáncer.
MX2019010086A 2017-02-27 2018-02-26 Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1. MX2019010086A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762463871P 2017-02-27 2017-02-27
PCT/IB2018/051184 WO2018154529A1 (en) 2017-02-27 2018-02-26 Dosing schedule for a combination of ceritinib and an anti-pd-1 antibody molecule

Publications (1)

Publication Number Publication Date
MX2019010086A true MX2019010086A (es) 2020-02-12

Family

ID=61622633

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019010086A MX2019010086A (es) 2017-02-27 2018-02-26 Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1.

Country Status (11)

Country Link
US (1) US20200069685A1 (es)
EP (1) EP3585486A1 (es)
JP (1) JP2020508353A (es)
KR (1) KR20190107719A (es)
CN (1) CN110461417A (es)
AU (1) AU2018223349A1 (es)
BR (1) BR112019017696A2 (es)
CA (1) CA3053469A1 (es)
MX (1) MX2019010086A (es)
RU (1) RU2019126627A (es)
WO (1) WO2018154529A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42447A (fr) 2015-07-13 2018-05-23 Cytomx Therapeutics Inc Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation
BR112021016795A8 (pt) * 2019-02-27 2022-08-16 Millennium Pharm Inc Administração de inibidor de enzima de ativação de sumo e inibidores de checkpoint

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
WO2007005874A2 (en) 2005-07-01 2007-01-11 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CA2671744C (en) 2006-12-08 2012-08-28 Irm Llc Compounds and compositions as protein kinase inhibitors
ES2616355T3 (es) 2007-06-18 2017-06-12 Merck Sharp & Dohme B.V. Anticuerpos para el receptor humano de muerte programada PD-1
RU2531758C2 (ru) 2008-02-11 2014-10-27 Куретек Лтд. Моноклональные антитела для лечения опухолей
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
EP2662383A1 (en) 2008-08-25 2013-11-13 Amplimmune, Inc. PD-I antagonists and methods for treating infectious disease
PT4209510T (pt) 2008-12-09 2024-04-02 Hoffmann La Roche Anticorpos anti-pm-l1 e a sua utilização para a melhoria do funcionamento das células t
JP5844159B2 (ja) 2009-02-09 2016-01-13 ユニヴェルシテ デクス−マルセイユＵｎｉｖｅｒｓｉｔｅ Ｄ’Ａｉｘ−Ｍａｒｓｅｉｌｌｅ Ｐｄ−１抗体およびｐｄ−ｌ１抗体ならびにその使用
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
US11344620B2 (en) * 2014-09-13 2022-05-31 Novartis Ag Combination therapies

Also Published As

Publication number Publication date
RU2019126627A (ru) 2021-03-29
JP2020508353A (ja) 2020-03-19
US20200069685A1 (en) 2020-03-05
KR20190107719A (ko) 2019-09-20
CA3053469A1 (en) 2018-08-30
CN110461417A (zh) 2019-11-15
BR112019017696A2 (pt) 2020-04-07
WO2018154529A1 (en) 2018-08-30
EP3585486A1 (en) 2020-01-01
AU2018223349A1 (en) 2019-08-29

Similar Documents

Publication Publication Date Title
MX2019009630A (es) Programa de dosificacion de un inhibidor de wnt y una molecula de anticuerpo anti-pd-1 en combinacion.
MX2018015393A (es) Anticuerpo lag-3, fragmento de union al antigeno del mismo y aplicacion farmaceutica del mismo.
MX2017001976A (es) Terapia de combinacion de anticuerpos activadores de la cd40 humana y anticuerpos contra el mp-l1 humano.
EP4374852A3 (en) Anti-cdh6 antibody and anti-cdh6 antibody-drug conjugate
MX2019011117A (es) Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos.
PH12018500174A1 (en) Combined use of anti pd-1 and anti m-csf antibodies in the treatment of cancer
MY194586A (en) Anti-garp antibody
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2016008362A (es) Combinaciones farmaceuticas.
MX2017017138A (es) Conjugados homogeneos especificos de sitio con inhibidores de ksp.
MX2015010791A (es) Metodos para tratar el cancer y prevenir la resistencia a farmacos.
MA39765A (fr) Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation
PH12016502352A1 (en) Pharmaceutical composition
PH12018500254A1 (en) Combinations of an ox40 antibody and a tlr4 modulator and uses thereof
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
AU2018256669A1 (en) Combination therapy
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX356704B (es) Combinación.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2019005309A (es) Anticuerpos anti-bag3 en combinacion con inhibidores del punto de control inmunitario para uso terapeutico.
MX2018007925A (es) Anticuerpo pcsk9, fragmento de union al antigeno y aplicacion medica del mismo.
MX2019010086A (es) Esquema de dosificacion para una combinacion de ceritinib y una molecula de anticuerpo anti-pd-1.
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2014012321A (es) Combinacion de analogos de somatostatina con inhibidores de 11-beta-hidroxilasa.
MX2013002503A (es) Combinacion de inhibidores de hdac con farmacos para trombocitopenia.